Status:
COMPLETED
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions
Lead Sponsor:
Roxane Laboratories
Conditions:
Hypertension
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The objective of this study was to prove the bioequivalence of Ramipril 10 mg capsules under fed conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion
- Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Ramipril or any comparable or similar product.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00702260
Start Date
January 1 2005
End Date
January 1 2005
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CEDRA Clinical Research, LLC
Austin, Texas, United States, 78759